Sun Pharmaceutical announced an update on the pre-clinical molecule. The experimental New Chemical Entity (NCE), GL0034, is a long-acting GLP-1R (Glucagon-Like Peptide-1 Receptor) agonist. Such agonists are used to treating patients with type 2 diabetes, including short-acting, intermediate-acting, and long-acting therapies.
The pre-clinical data for GL0034 was recently presented at the American Diabetes Association (ADA) Virtual 80th Scientific Sessions. GL0034 has been developed internally by Sun Pharma’s High Impact Innovations – Sustainable Health Solutions (HISHS) Discovery Team.
The pre-clinical performance of GL0034 was assessed in a highly relevant type 2 diabetes db/db mouse model. The NCE demonstrated significant outcomes on various diabetic parameters evaluated, such as glucose reduction, decrease in HbA1c (an important marker for clinical efficacy), augmented insulin secretion, lowering of glucagon level, and a marked and meaningful reduction in triglyceride levels. All these outcomes with GL0034 were found to be higher or significant to the currently marketed once a week GLP-1R agonists compared to the study. Yet another important feature in diabetes treatment is weight management. GL0034 induced a larger bodyweight reduction, 1.9x and 3.8x times higher than the two different standards once a week GLP-1R agonist drugs compared in the study, with similar food consumption.
Dilip Shanghvi, managing director, Sun Pharma said, “We are excited by the robust preclinical data for GL0034 and believe that it has significant potential. We look forward to validating this data in human clinical trials.”
According to the press release, Sun Pharma is planning to initiate Phase-1 clinical trials for GL0034 by Q3FY21.
